Diltiazem, 90 mg 30 pcs

Selective class III calcium channel blocker, benzothiazepine derivative.

Diltiazem has antianginal, hypotensive and antiarrhythmic effect. It reduces myocardial contractility, slows AV conduction, reduces heart rate, reduces myocardial oxygen demand, dilates coronary arteries, increases coronary blood flow. Diltiazem decreases peripheral arterial smooth muscle tone and RPS.

Decreases intracellular calcium ion content in cardiomyocytes and vascular smooth muscle cells, decreases HR, may cause a slight negative inotropic effect, increases coronary, cerebral and renal blood flow.

In concentrations with no negative inotropic effect, Diltiazem causes relaxation of coronary smooth muscle and dilatation of both large and small arteries.

Indications

Prevention of angina attacks (including Prinzmetal’s angina).

Arterial hypertension.

Prevention of supraventricular arrhythmias (paroxysmal supraventricular tachycardia, atrial fibrillation, atrial flutter, extrasystole).

Pharmacological effect

Selective class III calcium channel blocker, benzothiazepine derivative.

Diltiazem has antianginal, hypotensive and antiarrhythmic effects. Reduces myocardial contractility, slows AV conduction, reduces heart rate, reduces myocardial oxygen demand, dilates coronary arteries, increases coronary blood flow. Diltiazem reduces the tone of the smooth muscles of peripheral arteries and peripheral vascular resistance.

Reduces the intracellular content of calcium ions in cardiomyocytes and smooth muscle cells of blood vessels, reduces heart rate, may have a slight negative inotropic effect, increases coronary, cerebral and renal blood flow.

At concentrations at which there is no negative inotropic effect, Diltiazem causes relaxation of coronary smooth muscle and dilatation of both large and small arteries.

Special instructions

Diltiazem is used with caution in AV blockade of the first degree, intraventricular conduction disorders, in patients prone to arterial hypotension, chronic heart failure, myocardial infarction with left ventricular failure, ventricular tachycardia with expansion of the ORS complex, liver failure, renal failure, in elderly patients, in children (the effectiveness and safety of use have not been studied).

Active ingredient

Diltiazem

Composition

1 tablet contains diltiazem chloride 90 mg.

Contraindications

Severe bradycardia, AV block II and III degrees (except for patients with a pacemaker), SSSU, cardiogenic shock, atrial fibrillation in WPW and Lown-Ganog-Levin syndrome, myocardial infarction with pulmonary congestion, arterial hypotension, chronic heart failure stages II B-III, acute heart failure, hemodynamically significant aortic stenosis, liver and kidney dysfunction, pregnancy, lactation, hypersensitivity to benzothiazepine derivatives.

Side Effects

From the nervous system and sensory organs: headache, dizziness, fainting, increased fatigue, asthenia, sleep disturbances, drowsiness, anxiety, extrapyramidal (parkinsonism) disorders (ataxia, mask-like face, shuffling gait, stiffness of the arms or legs, trembling of the hands and fingers, difficulty swallowing), depression; when used in high doses – paresthesia, tremor, visual impairment (transient loss of vision).

From the cardiovascular system: asymptomatic decrease in blood pressure; rarely – angina pectoris, arrhythmia (including ventricular flutter and fibrillation), bradycardia (less than 50 beats/min) or tachycardia, AV block II-III degree. up to asystole, development or worsening of heart failure; when used in high doses and with intravenous administration – angina pectoris, bradycardia, AV block, marked decrease in blood pressure, worsening chronic heart failure.

From the digestive system: dry mouth, increased appetite, nausea, vomiting, constipation or diarrhea, increased activity of liver transaminases, gum hyperplasia (bleeding, pain, swelling).

From the hematopoietic system: rarely – thrombocytopenia, agranulocytosis.

Interaction

Potentially dangerous are combinations with beta-blockers, quinidine and other class Ia antiarrhythmic drugs, cardiac glycosides (excessive bradycardia, slowing of AV conduction, decreased myocardial contractility with the development of signs of heart failure). Procainamide, quinidine and other drugs that cause prolongation of the Q-T interval increase the risk of its significant prolongation.

May increase the bioavailability of propranolol. Inhalation anesthesia agents (hydrocarbon derivatives), thiazide diuretics and other drugs that lower blood pressure enhance the hypotensive effect of diltiazem.

Storage conditions

Store out of the reach of children at a temperature not exceeding 25°C.

Shelf life

2 years.

Manufacturer

Alkaloid AD Skopje, Republic of North Macedonia